1. Home
  2. RUN vs SRPT Comparison

RUN vs SRPT Comparison

Compare RUN & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RUN

Sunrun Inc.

HOLD

Current Price

$8.82

Market Cap

2.4B

Sector

Miscellaneous

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$20.95

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUN
SRPT
Founded
2007
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
2015
2000

Fundamental Metrics

Financial Performance
Metric
RUN
SRPT
Price
$8.82
$20.95
Analyst Decision
Buy
Hold
Analyst Count
20
29
Target Price
$18.80
$25.85
AVG Volume (30 Days)
8.3M
2.9M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
113.35
N/A
EPS
1.04
2.99
Revenue
$858,578,000.00
$2,198,237,000.00
Revenue This Year
$2.81
N/A
Revenue Next Year
$4.54
N/A
P/E Ratio
$8.71
$7.22
Revenue Growth
12.97
15.58
52 Week Low
$8.61
$14.68
52 Week High
$22.44
$25.32

Technical Indicators

Market Signals
Indicator
RUN
SRPT
Relative Strength Index (RSI) 37.58 71.58
Support Level $8.61 $20.12
Resistance Level $11.19 $23.71
Average True Range (ATR) 0.44 1.10
MACD 0.02 0.37
Stochastic Oscillator 3.56 84.24

Price Performance

Historical Comparison
RUN
SRPT

About RUN Sunrun Inc.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: